utilized a lipid‐based carrier to deliver Syk ASO to the lungs of rats with ovalbumin (OVA)‐induced allergic asthma, which led to a 71% reduction in the total cell count in bronchoalveolar lavage (BAL), with neutrophil counts decreasing by 74%, eosinophil counts by 85.2% and macrophages returning to normal levels.[281] Effective doses of Syk ASO demonstrated robust anti‐inflammatory effects and inhibited tracheal constriction by more than 50%. The gene discussed is SYK; the disease is allergic asthma.